Pure Global AI
2022-000179-38Ongoing

Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD

Bispebjerg HospitalEU Clinical Trials Register
VerifiedEU Clinical Trials Register
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Sponsor & location
Primary sponsor
Bispebjerg Hospital
Funder
AstraZeneca
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
Primary outcome

1. Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject’s ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
EU Clinical Trials Register
Trial ID
2022-000179-38
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for 2022-000179-38 through Pure Global AI's free database. This phase not specified trial is sponsored by Bispebjerg Hospital and is currently Ongoing. The study focuses on Chronic Obstructive Pulmonary Disease (COPD).

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.